Utama › Limfoma Folikular › New York › New York City
Kajian klinikal Limfoma Folikular di New York City, NY
24 kajian untuk Limfoma Folikular sedang mencari peserta di lokasi dalam dan sekitar New York City (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Mengambil pesertaFasa 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Mengambil pesertaFasa 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Mengambil pesertaFasa 1/2
- Research Site, New York
- Research Site, New York
Epco, Zanu, Ritux for R/R FL or MZL
Mengambil pesertaFasa 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Mengambil pesertaFasa 1
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Mengambil pesertaFasa 1/2
- New York University Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Mengambil pesertaFasa 1
- Columbia University, New York
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Mengambil pesertaFasa 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Mengambil pesertaFasa 2
- Research Site, New York
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Mengambil pesertaFasa 3
- Mount Sinai Medical Center, New York
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Mengambil pesertaFasa 3
- Icahn School of Medicine at Mt Sinai, New York
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Mengambil pesertaFasa 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Mengambil pesertaFasa 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- dan 1 lagi
A Study of ARC-02 in B-cell NHL
Mengambil pesertaFasa 1
- NYU Langone, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Mengambil pesertaFasa 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
Mengambil peserta
- New York State Psychiatric Institute (NYSPI) / Substance Treatment and Research Service (STARS), New York
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Mengambil pesertaFasa 2
- Memorial Sloan Kettering Cancer Center, New York
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Mengambil pesertaFasa 1
- Memorial Sloan Kettering Cancer Center - Bergen, New York
Chronic CED of TPT for Recurrent Malignant Glioma
Mengambil pesertaFasa 1
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Mengambil pesertaFasa 2
- Icahn School of Medicine at Mount Sinai Hospital, New York
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Mengambil pesertaFasa 2
- Icahn School of Medicine at Mount Sinai, New York
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Mengambil pesertaFasa 3
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of SGR-1505 in Mature B-Cell Neoplasms
Mengambil pesertaFasa 1
- Weill Cornell, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, New York
Kajian Limfoma Folikular di bandar lain
- Milwaukee, WI19 kajian
- Nashville, TN18 kajian
- Houston, TX18 kajian
- Boston, MA17 kajian
- Baldwin Park, CA16 kajian
- Seattle, WA15 kajian
- Durham, NC15 kajian
- Salt Lake City, UT13 kajian
- Columbus, OH13 kajian
- Chicago, IL12 kajian
- San Antonio, TX12 kajian
- Philadelphia, PA12 kajian
Kajian lain di New York City
- Kanser Payudara136 kajian
- Kanser Paru-paru Bukan Sel Kecil121 kajian
- Kanser (semua jenis)109 kajian
- Kanser Prostat103 kajian
- Kanser Metastatik93 kajian
- Kanser Kolorektal78 kajian
- Kanser Ovari69 kajian
- Kanser Paru-paru60 kajian
- Mieloma Pelbagai60 kajian
- Kanser Pankreas60 kajian
- Kanser Endometrium52 kajian
- Leukemia Mieloid Akut51 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.